Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19086995rdf:typepubmed:Citationlld:pubmed
pubmed-article:19086995lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C0021083lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C0337493lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C0023517lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C2921106lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C1540289lld:lifeskim
pubmed-article:19086995lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:19086995pubmed:issue1lld:pubmed
pubmed-article:19086995pubmed:dateCreated2008-12-17lld:pubmed
pubmed-article:19086995pubmed:abstractTextThe allogeneic leukocytes in transfused blood can modulate the recipient's immune system so as to induce TGF-beta-producing suppressor cells, and the cell-surface CD200 tolerance-signaling molecule on mononuclear dendritic cells is required for this effect. A subset of couples with unexplained recurrent pregnancy loss appears to benefit from transfusion of allogeneic paternal blood leukocytes (LIT), and considerable effort has been devoted to characterizing those who may benefit. Some data has been accumulated for LIT as sole therapy in patients with classical spontaneous abortions with respect to dose-response, duration of protection, need for boosting, excluding patients with autoimmunity, and inefficacy of paternal mononuclear cells stored at 4 degrees C overnight before use which causes loss of cell-surface CD200. Recent data emphasize an important role of expression of the CD200 tolerance-signaling molecule on cells used to prevent abortions both in mice and humans.lld:pubmed
pubmed-article:19086995pubmed:languageenglld:pubmed
pubmed-article:19086995pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19086995pubmed:citationSubsetIMlld:pubmed
pubmed-article:19086995pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19086995pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19086995pubmed:statusMEDLINElld:pubmed
pubmed-article:19086995pubmed:monthJanlld:pubmed
pubmed-article:19086995pubmed:issn1600-0897lld:pubmed
pubmed-article:19086995pubmed:authorpubmed-author:ClarkDavid...lld:pubmed
pubmed-article:19086995pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19086995pubmed:volume61lld:pubmed
pubmed-article:19086995pubmed:ownerNLMlld:pubmed
pubmed-article:19086995pubmed:authorsCompleteYlld:pubmed
pubmed-article:19086995pubmed:pagination75-84lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:meshHeadingpubmed-meshheading:19086995...lld:pubmed
pubmed-article:19086995pubmed:year2009lld:pubmed
pubmed-article:19086995pubmed:articleTitleCell-surface CD200 may predict efficacy of paternal mononuclear leukocyte immunotherapy in treatment of human recurrent pregnancy loss.lld:pubmed
pubmed-article:19086995pubmed:affiliationDepartment of Medicine, Molecular Medicine & Pathology, Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada. clarkd@mcmaster.calld:pubmed
pubmed-article:19086995pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:4345entrezgene:pubmedpubmed-article:19086995lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19086995lld:entrezgene